Project Grant R44HL172541
Award Date
8/15/24
Completion Date
7/31/25
Dollars Obligated
$317K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Woodbine, MD 21797, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $694,385 Project Grant to the Rector & Visitors of the University of Virginia to develop a method for enhancing the delivery of adeno-associated virus (AAV) gene therapy to the heart. The goal is to improve the efficiency and safety of AAV-based gene therapies for treating cardiovascular diseases by utilizing ultrasound-mediated cavitation of microbubbles to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel triple gene therapy approach to treat ischemic heart failure. The $560,000 award to Baylor College of Medicine aims to determine the optimal dosage and evaluate the efficacy and initial safety of a combined treatment involving the induction of cardiomyocyte proliferation, direct cardiac reprogramming, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This $1,488,899 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two novel therapeutic compounds, YT-002 and YT-004, to preserve myocardial tissue and function following myocardial infarction. The research aims to optimize the drug formulations, conduct detailed pharmacokinetic and pharmacodynamic studies, and perform comprehensive long-term safety...
This $814,209 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to develop an innovative in vivo gene therapy approach for treating genetic blood disorders. The project aims to optimize nanoparticle formulations that can be loaded with gene-editing agents and functionalized to target hematopoietic stem cells, allowing for direct administration into the bone marrow. This approach...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $298,368 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a common cardiovascular condition. The project aims to optimize the device design and procedure through bench testing, followed by conducting in vivo...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $559,138 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivacelle Bio Inc. to support the development of VBI-1, a novel treatment protocol for outpatient cardiac arrest. VBI-1 is a proprietary formulation of micelles and liposomes designed to act as a colloidal volume expander, absorb excessive nitric oxide and free radicals, and carry and release oxygen to address cardiac ischemia-reperfusion...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development and validation of a novel biodegradable hydrogel gene delivery system for targeted prevention of intimal hyperplasia and prosthetic bypass graft failure. The $786,188 award to Beth Israel Deaconess Medical Center, Inc. aims to optimize the efficiency and efficacy of this gene therapy platform by increasing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This $1,088,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research program with three independent projects related to genetic and molecular mechanisms of heart disease. The first project aims to define microRNA targeting events and their biological relevance in the heart, as well as understand the clinical significance of genetic variants that alter cardiovascular microRNA...